SAN FRANCISCO -- Radiation therapy (RT) after surgery for high-risk muscle-invasive bladder cancer significantly reduced the rate of local recurrence and improved survival, according to a randomized ...
By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.
Trimodal therapy consisting of radiation plus chemotherapy and transurethral resection is an effective potential alternative to radical cystectomy for high-grade T1 bladder cancer. Trimodal therapy is ...
An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and ...
UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...
First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival ...
Having high levels of the biomarker carbohydrate antigen 19-9 before surgery is associated with bladder cancer recurrence among patients who undergo radical cystectomy. In patients with bladder cancer ...
Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...
Zusduri demonstrated a 72.2% 24-month response durability in LG-IR-NMIBC patients, leading to FDA approval as a non-surgical treatment option. The ENVISION trial enrolled 240 patients, focusing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback